We reiterate our OUTPERFORM recommendation on Nexstim and ahead of what is likely to be an exciting year of news flow, we increase our target price to €1.23 (from €0.93). We believe the risk reward relationship is very lucrative - the company is on the way to developing a new therapy platform of NBT system with appealing recurring revenue. Recent FDA approval for depression reduces the risks as the platform is not solely based on stroke rehabilitation anymore.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2018: An exciting year ahead
We reiterate our OUTPERFORM recommendation on Nexstim and ahead of what is likely to be an exciting year of news flow, we increase our target price to €1.23 (from €0.93). We believe the risk reward relationship is very lucrative - the company is on the way to developing a new therapy platform of NBT system with appealing recurring revenue. Recent FDA approval for depression reduces the risks as the platform is not solely based on stroke rehabilitation anymore.